The company's drug development program targets the enzyme system that controls the proliferation of cancer stem cells, with the goal of preventing metastatic breast cancer and other CSC-mediated diseases such as ovarian, pancreatic, colon, melanoma, lung, and liver cancers. EpiAxis aims to become a leading company in cancer recurrence prevention by including its proprietary inhibitors in the standard of care for cancer treatment.